

1 **A HOME-TREATMENT ALGORITHM BASED ON ANTI-INFLAMMATORY DRUGS TO**
2 **PREVENT HOSPITALIZATION OF PATIENTS WITH EARLY COVID-19:**
3 ***A MATCHED-COHORT STUDY (COVER 2)***

4
5
6 ELENA CONSOLARO MD¹, FREDY SUTER MD², NADIA RUBIS[†] RES NURSE³, STEFANIA PEDRONI MD¹,
7 CHIARA MORONI MD¹, ELENA PASTÒ MD¹, MARIA VITTORIA PAGANINI MD¹,
8 GRAZIA PRAVETTONI MD⁴, UMBERTO CANTARELLI MD⁵, NORBERTO PERICO* MD³,
9 ANNALISA PERNA MSC³, TOBIA PERACCHI STATSCID³, PIERO RUGGENENTI* MD^{2,3},
10 GIUSEPPE REMUZZI *MD³

11
12 ¹*ATS Insubria, Varese, Italy*

13 ²*Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy*

14 ³*Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy*

15 ⁴*Ospedale Circolo di Busto Arsizio, Varese, Italy*

16 ⁵*ASL Teramo, Teramo, Italy*

17
18 * These authors have contributed equally to this work

19
20 Running title: Early COVID-19 treatment at home

21 Word count: 4663; Figures: 2; Tables: 4. Supplementary material

22 [†]*Correspondence to:*

23 Nadia Rubis Res Nurse,

24 Istituto di Ricerche Farmacologiche Mario Negri IRCCS,

25 Centro di Ricerche Cliniche per Malattie Rare Aldo e Cele Daccò,

26 Via GB Camozzi 3, 24020 Ranica, Bergamo, Italy.

27 Email: nadia.rubis@marionegri.it

28

29

ABSTRACT

30 **Background and Aim:** While considerable success has been achieved in the management of
31 patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been
32 made with early outpatient treatment. We assessed whether the implementation of a home treatment
33 algorithm – designed based upon on a pathophysiologic and pharmacologic rationale - during the
34 initial, mild phase of COVID-19, could effectively reduce hospital admissions.

35 **Methods:** This fully academic, matched-cohort study evaluated outcomes in 108 consecutive
36 consenting patients with mild COVID-19 managed at home by their family doctors from January
37 2021 to May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and
38 comorbidities-matched patients who were given other therapeutic schedules (ClinicalTrials.gov:
39 NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by
40 intention-to-treat.

41 **Results:** One (0.9%) patient in the ‘recommended’ cohort and 12 (11.1%) in the ‘control’ cohort
42 were admitted to hospital (P=0.0136). The proposed algorithm reduced, by 85%, the cumulative
43 length of hospital stays (from 141 to 19 days) and related costs (from €60.316 to €9.058). Only 9.8
44 patients needed to be treated with the recommended algorithm to prevent one hospitalization event.
45 The rate of resolution of major symptoms was numerically, but not significantly, higher in the
46 ‘recommended’ compared to the ‘control’ cohort (97.2% versus 93.5%, respectively; P=0.322).
47 Other symptoms lingered in a lower proportion of patients in the ‘recommended’ than in the
48 ‘control’ cohort (20.4% versus 63.9%, respectively; P<0.001), and for a shorter period.

49 **Conclusion:** The adoption of the proposed outpatient treatment algorithm during the early, mild
50 phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs.

51

52 **Keywords:** COVID-19, SARS-CoV-2, hospitalization, outpatients, at home management.

53

54 **1. INTRODUCTION**

55

56 Over the past two years the novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome
57 Coronavirus 2), which causes coronavirus disease 2019 (COVID-19), has quickly spread globally,
58 reaching pandemic proportions (1). Through genetic evolution resulting in multiple variants (2),
59 SARS-CoV-2 has been responsible for several pandemic waves worldwide (1). The clinical
60 manifestations of COVID-19 disease are broad, spanning asymptomatic infection, mild upper
61 respiratory tract and/or mild extrapulmonary symptoms, and including severe pneumonia, acute
62 respiratory distress syndrome and multiorgan system dysfunction, and even death (3,4). During the
63 early phase of COVID-19 when patients are at home they are usually not seriously ill with acute
64 respiratory distress, but present a variety of initially mild/moderate symptoms, including fever,
65 cough, tiredness, shortness of breath and chills, a sore throat, headache, musculoskeletal pain, and a
66 new loss of taste and smell (5).

67 While drug/biological treatment options for severely ill COVID-19 patients requiring
68 hospitalization are now available (6–11), interventions that can be administered by primary care
69 physicians at home have been more difficult to determine and controversial (12). Nonetheless, the
70 early initiation of treatment for COVID-19 might improve clinical outcomes, providing a potential
71 window for immediate benefits by intervening before the development of severe disease, and
72 possibly limiting or preventing the risk of patient hospitalization.

73 Although guidelines or recommendations for managing patients with suspected or confirmed
74 COVID-19 in the community have recently been made available by national health authorities
75 (13,14), most family doctors initially treated their patients with various treatment regimens they
76 believed appropriate based on their clinical expertise. Based on the increasing available knowledge
77 on the pathophysiology underlying the mild/moderate symptoms encountered at the onset of the
78 illness (15,16), we recently published a proposed regimen of simple drugs that should theoretically
79 better fit these mechanisms (17). The proposed treatment recommendation (17) is based on three

80 pillars: i) intervene at the very onset of mild/moderate symptoms at home; ii) start therapy as early
81 as possible after the family doctor has been contacted by the patient, without awaiting the results of
82 a nasopharyngeal swab; iii) rely on non-steroidal anti-inflammatory drugs, especially relatively
83 selective cyclooxygenase-2 (COX-2) inhibitors (18,19), an approach intended to limit excessive
84 host inflammatory responses to viral infection (16,17).

85 In a recent academic matched-cohort study (20), we found that early treatment of COVID-19
86 patients at home by their family doctors, according to the proposed recommendation regimen,
87 almost completely prevented the need for hospital admission due to progression toward more severe
88 illness (2 out of 90 patients), compared to patients in the ‘control’ cohort, who were treated at home
89 according to their family physician’s assessments (13 out of 90 patients). However, the rate of
90 hospitalization was a secondary outcome of the study, and the possibility that this is a random
91 finding cannot be excluded definitely. Thus, we considered the observed reduction in patient
92 hospitalizations a hypothesis-generating finding that provides the background for the present, new
93 matched-cohort study. The primary aim of this study was to test the effect of COVID-19 treatment
94 at home on this outcome, according to the proposed recommendation algorithm.

95

96 **2. MATERIALS AND METHODS**

97

98 *2.1 Study design and participants*

99 This in an observational study that involved two matched cohorts of COVID-19 patients.

100 The ‘recommended algorithm’ cohort included 108 patients treated at home by their family
101 physicians who expressed interest in participating in the study and followed the published proposed
102 treatment recommendation (see Supplementary Methods) (17). They were from the Varese,
103 Bergamo, and Teramo provinces (Italy) and prospectively engaged their patients between January
104 and May 2021. These family doctors applied the recommended algorithm at the onset of symptoms,
105 or within a few days of being contacted by patients. The physicians provided patients with detailed
106 information about the objectives and design of study and collected signed consent forms. They were
107 asked to complete an online questionnaire with information on the outcomes of COVID-19
108 symptoms/illness that are relevant to addressing the primary, secondary and safety aims of the
109 study. The Istituto di Ricerche Farmacologiche Mario Negri IRCCS (Bergamo, Italy) was the
110 coordinator of the project, promoted through online institutional media. Male and female adults,
111 aged ≥ 18 years, with early mild symptoms of COVID-19, who started the recommended treatment
112 without awaiting the results of a nasopharyngeal swab, if any, were eligible to participate in the
113 study.

114 As a control cohort, 108 historic COVID-19 patients were retrospectively considered. These
115 patients had been enrolled in the “Study of the Genetic Factors that Influence the Susceptibility to
116 and Severity of COVID-19” (the ORIGIN study, conducted by the Istituto di Ricerche
117 Farmacologiche Mario Negri, IRCCS (ClinicalTrials.gov; NCT04799834), and treated at home by
118 their family doctors with drug regimens not necessarily guided by those proposed in the
119 recommendation algorithm. They were matched by age, sex, comorbidities (hypertension, diabetes,
120 cardiovascular diseases, overweight, chronic kidney disease) with patients in the ‘recommended

121 algorithm' cohort. Notably, the ORIGIN study collects, among other things, all clinical information
122 intended for the analyses of the 'recommended algorithm' cohort from the population of COVID-19
123 patients living in the Bergamo province.

124 In both cohorts, subjects who required immediate hospitalization, according to the family
125 physician's assessment, because of severe COVID-19 symptoms at onset, were excluded.

126

127 *2.2 Outcome variables*

128 The primary outcome was the proportion of patients requiring hospitalization due to clinical
129 worsening of the illness in the two treatment cohorts.

130 Secondary outcomes included: i) Compliance to the algorithm in the cohort that adopted the
131 proposed treatment recommendations, defined as adherence to recommended schedule of treatment;

132 ii) Number of days between onset of symptoms and the start of anti-inflammatory therapy; iii) The
133 proportion of patients in the two cohorts with complete resolution of major symptoms ('complete
134 remission') defined as recovery from these symptoms, namely no fever, SpO₂ >94% and/or no

135 dyspnea, cough, rhinitis, pain (myalgia, arthralgia, chest pain, headache, sore throat), vertigo,
136 nausea, vomiting or diarrhea, sicca syndrome or red eyes; iv) The proportion of patients in the two

137 cohorts with persistent other symptoms, such as anosmia, ageusia/dysgeusia, lack of appetite,
138 fatigue. In addition, the duration of persistence of these symptoms (<30 days, or 30 to 60, or >60

139 days) was evaluated; v) Time (in days) spent in an intensive care unit, sub-intensive care unit, and
140 ordinary units by patients who required hospital admission in the two cohorts; vi) Cumulative

141 hospitalization costs (in euro) for patients admitted to hospital in the two cohorts. Potential baseline
142 confounders such as age, sex, and concomitant diseases that could increase the risk of severe

143 COVID-19 illness were predefined (21–23). Moreover, serious (SAE) and non-serious adverse
144 events (AE) related to the administered treatments according to recommendations were assessed.

145 The severity/non-severity of the observed events and their causal relationships with treatments were
146 determined by the family doctor in charge of the patients.

147

148 *2.3 Samples size and statistical analysis*

149 Based on our recent findings (20), we assumed that the proportion of hospital admissions in the
150 ‘historic control’ cohort, when patients were treated by their family doctors according to drug
151 regimens not necessarily guided by those proposed in our recommendation algorithm, is 0.1444,
152 and that in the ‘recommended algorithm’ cohort it is 0.0222. Based on the above assumption, a
153 sample size of 85 patients per group (170 total) would achieve 80% power to detect a difference
154 between the group proportions of 0.1222 (two-sided log rank test, alpha=0.05). Assuming a 20%
155 drop-out rate, 106 per group (i.e. 212 total) needed to be included.

156 The ‘recommended algorithm’ and ‘historic control’ cohorts were expected to be sufficiently
157 comparable at baseline. However, matching was carried out between the two groups (24). The SAS
158 PROC LOGISTIC was used to calculate the predicted probability of the dependent variable - the
159 Propensity Score - for each observation in the data set. This single score (between 0 and 1)
160 represents the relationship between multiple characteristics (i.e., the following baseline variables:
161 age, sex, and comorbidities) and the dependent variable (i.e., the treatment group) as a single
162 characteristic. Then the propensity score represents the predicted probability of receiving treatment.
163 Using the SAS %MACRO OneToManyMTCH, the 108 ‘recommended algorithm’ individuals were
164 matched to 108 ‘control’ subjects with the closest propensity score. Moreover, to verify the
165 robustness of the above-described propensity score method, a further exploratory approach was
166 performed by using the ‘teffects iptw’ STATA command to estimate the average treatment effect
167 from observational data by inverse probability treatment weighting (IPTW), including 3368 patients
168 in the control ORIGIN database.

169 Continuous variables were analyzed through descriptive statistics and reported as mean (SD) or
170 median [IQR], as appropriate. Within-group changes with respect to baseline were analyzed with
171 paired t-test or Wilcoxon signed-rank test, as appropriate. To determine the proportion of patients
172 who required hospitalization a Log-rank test was used.

173 The cumulative costs for hospitalization in the two cohorts were the arithmetic sum of the direct
174 cost of stay in an ordinary ward, sub-intensive care unit and intensive care unit for the entire period
175 of hospitalization. In particular, in each cohort the total number of days that all patients spent in
176 each of the three units of the hospital was multiplied by the corresponding estimated direct cost of
177 stay per day (i.e., € 427, € 582, and € 1,278 per stay in an ordinary ward, and sub-intensive and
178 intensive care units, respectively). Then the cumulative costs were calculated as the sum of the
179 overall costs of stay in the three units. The direct cost per day was derived from data from a study
180 on the management of COVID-19 patients admitted to hospital (Azienda Ospedaliera Nazionale SS.
181 Antonio e Biagio e Cesare Arrigo, Alessandria, Italy) and the resources employed, performed by the
182 Associazione Italiana Ingegneri Gestionali in Sanità (Castellanza, Varese, Italy) and presented at the
183 LIUC Business School (Castellanza, Varese Italy) (<http://www.liucbs.it> – Webinar COVID, 8 July
184 2020).

185 All analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC) and Stata 15 (StataCorp,
186 College Station, TX). For the primary outcome a p-value of 0.05 was considered to determine
187 statistical significance. For the six secondary outcomes a Bonferroni-adjustment for multiple tests
188 was employed and a p-value of 0.0083 was used (25).

189

190 *2.4 Ethical aspects*

191 The COVER 2 study was approved by the Ethical Committee of Insubria (Varese, Italy; 27 July
192 2021) and registered at ClinicalTrials.gov (NCT04854824). In COVER 2, participants in the
193 ‘recommended algorithm’ cohort provided written informed consent to their family doctors at
194 enrolment. Subjects in the ‘control’ cohort (from the ORIGIN database) signed a consent form to
195 participate in the ORIGIN study, which also explicitly included consent to use their data for future
196 studies, such as COVER 2.

197

198 **3. RESULTS**

199

200 *3.1 Participants*

201 Eight family doctors reported treating 108 consenting patients with early COVID-19 symptoms at
202 home between January 2021 and May 2021, according to the proposed recommended algorithm
203 (17). All individuals in this ‘recommendation’ cohort, had positive nasopharyngeal swabs,
204 confirming SARS-CoV-2 infection. In 103 of 108 matched subjects identified in the ORIGIN
205 dataset (‘control’ cohort) the onset of COVID-19 symptoms occurred between late February and
206 July 2020, and in the other 5 participants between September 2020 and January 2021. SARS-CoV-2
207 infection was confirmed in all cases by nasopharyngeal swabs or serology tests. These individuals
208 were treated at home by their family physicians with drug regimens not necessarily guided by those
209 proposed in the recommendation algorithm. The cohorts were comparable in terms of mean age and
210 age range, with most subjects aged between 41 and 65 (Table 1). Females were more prevalent in
211 both cohorts (57.4% and 64.8%). The concomitant diseases were well distributed between the two
212 groups, except for overweight/obesity, which were reported in a few more individuals in the
213 ‘control’ cohort. The most common symptoms at the onset of illness were fever (70.4% vs 72.2%)
214 and tiredness (68.5% vs 76.9%), followed by cough (60.2% vs 48.2%), and myalgia (48.2% vs
215 53.7%) in both the ‘recommendation’ and ‘control’ cohorts (Table 1). More individuals in the
216 ‘recommended algorithm’ cohort had arthralgia (30.6% vs 3.7%, $P=0.001$), while ageusia was
217 significantly more frequent in the ‘control’ cohort (38.9% vs 55.6%, $P=0.020$). The distribution of
218 dyspnea was similar between the two groups (25.9% vs 31.5%, $P=0.452$).

219

220 *3.2 Primary outcome*

221 One of the 108 patients (0.9%) in the ‘recommended’ cohort was hospitalized, compared to 12 of
222 the 108 patients (11.1%) in the ‘control’ cohort (Figure 1). The event rate was significantly lower in
223 the ‘recommended’ than in the ‘control’ group (survival analysis for clustered data, $P=0.0136$)

224 (Figure 1). The patient in the ‘recommended’ cohort was admitted to hospital due to dyspnea
225 secondary to interstitial pneumonia (Table 2). This was the same reason for the hospitalization of all
226 patients in the ‘control’ cohort, except for one who was admitted with dyspnea due to documented
227 pulmonary thromboembolism (Table 2).

228 To confirm these findings, explorative analysis was performed using the inverse probability
229 weighting (IPTW) method, including 3368 patients in the control ORIGIN database. We found that
230 the hospitalization rate in the ‘recommended algorithm’ cohort was significantly lower than in the
231 ‘control’ cohort (-0.059; 95% CI, -0.077 to -0.041; $P < 0.0001$).

232

233 *3.3 Secondary outcomes*

234 Seventy-four of 108 ‘recommended’ cohort patients were treated with a relatively selective COX-2
235 inhibitor, such as nimesulide or celecoxib, while 15 patients were given aspirin (Table 3). Non-
236 adherence to the recommended anti-inflammatory regimen was 24.07%, since 26 patients were
237 prescribed other NSAIDs (ketoprofen, ibuprofen or paracetamol). In the ‘recommended’ cohort,
238 anti-inflammatory treatment with NSAIDs was prescribed by family physicians within a mean (\pm
239 SD) of 1.7 ± 3.3 days after the onset of symptoms, except for paracetamol that was self-
240 administered by the patients before contacting the doctor. At variance, in the ‘control’ cohort only
241 few patients received relatively selective COX-2 inhibitors ($n=4$) or aspirin ($n=5$) (Table 3).
242 Notably, in this cohort most patients were given paracetamol ($n=74$), and the remaining ketoprofen
243 or ibuprofen.

244 Corticosteroids were prescribed to 26% and 6.5% of patients in the ‘recommended’ and ‘control’
245 cohorts, respectively ($P < 0.001$) (Table 3). A median of 7 [IQR: 5-8.5] days elapsed between
246 starting NSAID and corticosteroid prescriptions in the ‘recommended’ group. More patients were
247 treated with antibiotics in the ‘recommended’ than in the ‘control’ cohort ($P=0.039$), while
248 anticoagulants were prescribed in very few cases in both groups (Table 3). Ten patients in the
249 ‘recommended’ cohort and two in the ‘control’ cohort required oxygen supply at home due to

250 decreasing oxygen saturation or following a first episode of dyspnea or wheezing (P=0.033) (Table
251 3).

252 Almost all patients achieved resolution of the major symptoms (i.e., complete remission), and the
253 event rate was numerically - but not significantly - higher in the recommended than in the 'control'
254 cohort between the two cohorts (P=0.332) (Table 4). On the other hand, the proportion of patients
255 with persistent other symptoms, such as anosmia, ageusia/dysgeusia, lack of appetite and fatigue
256 was significantly lower in the 'recommended' than in the 'control' cohort (20.4% vs 63.9%,
257 respectively; P<0.001) (Table 4). This difference was shown in the subgroups of patients with these
258 symptoms persisting for 30 to 60 days or more than 60 days (Table 4).

259 The single patient in the 'recommended' cohort who was hospitalized was discharged after 19 days,
260 compared to 12±7 (range, 4 to 26) days in the 12 patients in the 'control' cohort. The cumulative
261 length of hospital stays in the latter cohort reached 141 days (Table 2). At variance with the patient
262 in the 'recommended' cohort who spent 6 days in a sub-intensive care unit and 13 days in the
263 ordinary unit, none of the patients in the 'control' cohort required admission to sub-intensive care
264 units or an ICU, and all were managed in the ordinary hospital units (Table 2). Thus, cumulative
265 hospitalization costs were €9.058 and €60.316 in the 'recommended' and 'control' cohorts,
266 respectively (Figure 2). Only 9.8 (95% CI: 6.1 to 25.1) patients needed to be treated with the home
267 therapy algorithm to prevent one hospitalization event.

268 Regarding hospital admission, a sensitivity analysis was also performed after excluding patients
269 who spontaneously initiated paracetamol before the family doctor prescriptions in the
270 'recommended' cohort and the related matched patients in the 'control' cohort. Similarly to the
271 intention-to-treat analysis, only 1 of the 99 patients (1.01%) in the 'recommended' cohort required
272 hospital admission, compared to 10 of the 99 patients (10.1%) in the 'control' cohort. The event rate
273 was still significantly lower in the 'recommended' than in the 'control' cohort (survival analysis for
274 clustered data, P=0.0193).

275

276 **4. DISCUSSION**

277

278 In this observational matched-cohort study we found that COVID-19 patients being treated at home
279 early after the onset of symptoms by their family physicians according to the proposed
280 recommendation algorithm almost completely prevented the need for hospitalization due to severe
281 worsening of the illness (primary outcome of the study), compared to patients in the ‘control’
282 cohort, who were treated at home according to their family doctor’s judgment. This resulted in an
283 over 85% reduction in the length of hospital stays, which translated into a similar percentage of
284 lowered related treatment costs. Thus, the cost-effectiveness of the home recommendation treatment
285 algorithm was remarkable, considering that in the two cohorts the early symptoms were
286 comparable. In line with this observation, only 9.8 patients needed to be treated to prevent one
287 hospitalization event. These findings, achieved in a larger number of COVID-19 patients, further
288 corroborate the results of our previous matched-cohort study regarding the lower risk of hospital
289 admission in patients treated at home at the onset of illness according to the recommendation
290 algorithm (20), than with other regimens. Similarly, the rate of resolution of major COVID-19
291 symptoms, including fever, myalgias/arthralgias, headache and cough, was numerically higher in
292 the ‘recommended’ algorithm than in the ‘control’ cohort. Moreover, other symptoms, such as
293 anosmia or ageusia, or fatigue, ceased more frequently and persisted for a shorter period in the
294 ‘recommended’ than in the ‘control’ cohort. Together, these observations suggest that the two
295 regimens targeting early symptoms, not the virus, affected COVID-19 disease phenotype in
296 different ways, which translated into a remarkable decreased need for hospitalization in patients
297 treated according to the ‘recommended’ algorithm. Moreover, the lower hospitalization rate in this
298 cohort cannot be attributed to limited access to hospitals, since patients in the ‘recommended’
299 regimen group became ill during the third wave of the pandemic (from January 2021), when
300 hospital (human and technical) resources were brought close to but did not reach the limit at which
301 they would have been forced to deny hospital admission of those with severe COVID-19. This was

302 not the case for the ‘control’ cohort, in which most patients reported symptoms during the first stage
303 of the COVID-19 outbreak, when hospitals were under huge pressure, which may have resulted in
304 postponed or denied hospitalization for some patients in need. Thus, finding that there was a
305 remarkably higher hospitalization rate in the ‘control’ cohort provided additional evidence of the
306 protective effect of the proposed treatment algorithm against hospitalization because of worsening
307 COVID-19 symptoms.

308 Our recommendation treatment algorithm (17) is based on the idea that it is critical to intervene at
309 home very early on during the onset of mild/moderate symptoms to avoid progression toward
310 severe COVID-19, which would eventually require hospital admission. Indeed, after the initial
311 exposure to SARS-CoV-2, patients typically develop symptoms that indicate an inflammatory
312 process within 5 to 6 days on average (15,16), and pro-inflammatory mediators, in particular
313 cytokines, seem to be integral to the initiation, intensification, propagation and worsening of tissue
314 morbidity related to COVID-19 (16,19,26). Therefore, our recommended treatment algorithm
315 moved from this pathophysiologic rationale of early COVID-19 events, and focused on the initial
316 use of NSAIDs, which has been shown to reduce pro-inflammatory cytokine levels (18). NSAIDs
317 inhibit the cyclooxygenase activity of prostaglandin H synthase 1 and 2, also named COX-1 and
318 COX-2 (27). Relatively selective COX-2 inhibitors (e.g., celecoxib, etoricoxib) (27) may reduce
319 pro-inflammatory cytokine levels, as shown in mice with influenza A infection (TNF- α , G-CSF,
320 and IL-6) (28) and in hospitalized COVID-19 patients (IL-6) (19,29). The overlap in COX-2
321 selectivity between coxibs and the more traditional NSAID nimesulide (27) was the rationale for
322 recommending these drugs for the treatment of early COVID-19 at home, unless contraindicated.
323 Adherence to this recommendation was very high (75.3%) in the ‘recommended’ algorithm cohort.
324 On the other hand, in the ‘control’ cohort very few patients were treated with a COX-2 inhibitor,
325 and most received paracetamol. However, this drug, considered an alternative for addressing the
326 symptoms of COVID-19 in the early stages (14), has negligible anti-inflammatory effect (30), in
327 addition to being capable of inducing or worsening glutathione consumption (31,32). Given the

328 anti-oxidant property of glutathione, it has recently been hypothesized that paracetamol might even
329 exacerbate COVID-19 (31,32).

330 Physicians may be reluctant to use NSAIDs, including relatively selective COX-2 inhibitors, due to
331 the known risk of cardiovascular events (33) and the hepatotoxicity of nimesulide, which is
332 admittedly very low when the drug is prescribed at the recommended daily dose and time of
333 administration (34). On the other hand, in a large cohort of over 4200 patients admitted to the
334 hospital who had taken NSAIDs within the 2 weeks preceding hospital admission, the use of these
335 drugs was not associated with higher mortality or increased severity of COVID-19, as compared to
336 a matched group of NSAID non-users (35). Moreover, another study provided no indication that
337 harm was induced by NSAIDs, as demonstrated by the lack of increased risk of poorer outcomes in
338 COVID-19 patients given NSAIDs compared with those treated with paracetamol, or NSAID non-
339 users (36). None of the patients in the ‘recommended algorithm’ cohort developed toxicity related
340 to or possibly related to the use of celecoxib or nimesulide. This is in line with the fact that few
341 patients in this cohort received aspirin, which the recommendations propose as alternative therapy
342 when contraindications to celecoxib or nimesulide are highlighted by physicians. Notably, there is
343 evidence that aspirin may reduce plasma levels of pro-inflammatory cytokines (37), and lower the
344 risk of in-hospital mortality in a large cohort of patients hospitalized with COVID-19 (38),
345 supporting the use of this drug in the early stages of COVID-19 at home when needed. In the future,
346 other NSAIDs, such as indomethacin, which also lowers IL-6 in SARS-CoV-2 patients (39), could
347 be proposed as an alternative treatment for early COVID-19 symptoms at home, as anticipated by a
348 recent small Indian study (40).

349 The same pharmacologic rationale was adopted for the recommendation of the use of
350 corticosteroids, known to exert their anti-inflammatory effects mainly by inhibiting pro-
351 inflammatory genes that encode for cytokines and chemokines (41). Our proposal clearly suggests
352 only starting corticosteroid several days after the onset of symptoms if fever or musculoskeletal
353 pain persist despite NSAIDs or when oxygen saturation significantly declines. According to this, in

354 the ‘recommended algorithm’ cohort, corticosteroids were administered only after a median of 7
355 days after the onset of symptoms and when they fulfilled the proposed criteria for starting this class
356 of drugs, not necessarily limited to patients in need of oxygen supply. This might explain the
357 discrepancy between the number of patients treated with corticosteroids (n=28) and those given
358 oxygen therapy (n=10) in the ‘recommended’ cohort. Despite concerns about the use of
359 corticosteroids in COVID-19 patients due to the risk of complications and the possible persistence
360 of the virus in the host (42,43), no side effects related to the use of these drugs were reported in
361 patients of the ‘recommended’ cohort. Based on the large RECOVERY trial (10), WHO
362 recommended systemic corticosteroids only in hospitalized patients with severe COVID-19 who
363 require respiratory support (44). However, there is also some evidence of the benefit of
364 corticosteroids during the early phase of the illness (45,46), recently corroborated by findings of
365 randomized controlled trials with inhaled corticosteroids in the community (47,48). The
366 administration of inhaled budesonide within 7 days of the onset of mild COVID-19 symptoms
367 markedly reduced the risk of hospitalization compared to patients receiving the usual care, results
368 which are similar to those achieved in our ‘recommended algorithm’ cohort. Interestingly, the
369 recommendations of the Italian Ministry of Health for the management of COVID-19 patients at
370 home have recently been updated (14) to include corticosteroids for the treatment of early COVID-
371 19 symptoms according to criteria very similar to those proposed in our recommendation algorithm
372 (17).

373 Despite being recommended by the algorithm, especially for those bedridden or with high D-dimer
374 levels, only a small number of COVID-19 patients in the ‘recommendation’ cohort received a
375 prophylactic dose of LMW heparin. None of them had side effects. Actually, COVID-19 is
376 characterized by dysregulation of the coagulation system and fibrinolysis that can promote micro-
377 and macro-vascular thrombosis, as well as venous thromboembolic complications, which are
378 sometimes life-threatening (16,49,50). Even guidelines (14) suggest that LMW heparin be used at a
379 prophylactic dosage in COVID-19 patients at home in particular instances. Nonetheless, a recent

380 study involving 2219 noncritically ill, hospitalized COVID-19 patients reported that therapeutic-
381 dose anticoagulation with heparin increased the probability of in hospital survival compared with
382 standard care thromboprophylaxis, regardless of the patient's baseline D-dimer levels (51). This
383 finding creates the possibility of studying an initial strategy of therapeutic versus prophylactic
384 anticoagulation with LMW heparin in COVID-19 patients with moderate symptoms who are being
385 treated at home as well.

386 Similarly, the recommendation for antibiotic treatment was just in case of suspected bacterial
387 pneumonia or suspected secondary bacterial upper respiratory infections, not on a routine basis,
388 which is in line with the UK NICE COVID-19 guidelines for managing patients at home (13).
389 According to these indications, family doctors in the 'recommended algorithm' cohort used
390 antibiotics in 37% of their COVID-19 patients. This is not surprising, considering that in a
391 systematic review on hospitalized COVID-19 patients, 1450 of 2010 individuals (72%) were treated
392 with antibiotics, despite only 8% presenting with evidence of bacterial coinfection (52).
393 Nonetheless, the risk of developing antimicrobial resistance should invite caution regarding the
394 indiscriminate use of antibiotics.

395 The non-randomized design is a major limitation of the study, which is observational in nature.
396 Nonetheless, comparative analysis of patient cohorts in everyday clinical practice with adjustments
397 for possible confounding biases may offer a suitable alternative to the recommended clinical trials
398 to evaluate the effectiveness of different therapeutic regimens (53,54). Moreover, the matched-
399 cohort study protocol with a statistical plan was predefined and the analyses were performed
400 accordingly. There is the additional limitation that the collection of outcome information in the
401 'control' cohort was through interviews and questionnaires related to events that happened before
402 the survey. This was not the case for the 'recommended algorithm' cohort, where data were
403 gathered by family doctors. However, in both cohorts the date of hospital admission (primary
404 outcome) and data about the course of hospitalization were well documented in the hospital
405 discharge letter. Moreover, further evidence of the observed difference between the hospital

406 admission rates for the two cohorts is offered by the results of the additional explorative analysis of
407 3368 patients in the control ORIGIN database, which confirmed a significantly lower rate of
408 hospitalization in the ‘recommended algorithm’ than in the ‘control’ group.

409 On the other hand, the COVER 2 study formally tested outcomes for COVID-19 patients managed
410 by their family physicians according to a therapy recommendation algorithm that targets early
411 symptoms, based on the pathophysiology of the illness and the related pharmacologic rationale.
412 This is a strength of the COVER 2 study, since none of the recently proposed recommendations on
413 how to treat COVID-19 patients for family doctors in the community have been formally evaluated
414 on whether they can limit the progression of mild/moderate symptoms at the onset of the disease to
415 the need for hospital admission.

416 In conclusion, we have documented that simple, reasoned treatments for the early-phase symptoms
417 of COVID-19 at home, collected in a recommendation algorithm for family doctors, are beneficial
418 in clinical practice, since they may avoid or limit deterioration of the disease to the point of
419 hospitalization, in addition to having public health implications. Our findings also have important
420 implications for patient quality of life, since adopting the treatment recommendation approach
421 reduced the rate and shortened the duration of symptoms, such as loss of taste or smell, and fatigue,
422 which might otherwise persist for several months (55). Future randomized studies will be required
423 for the consolidation of these observational findings on the potential benefit of the proposed
424 treatment recommendation algorithm.

425

426

CONFLICT OF INTEREST STATEMENT

427 We declare that we have no conflicts of interest.

428

429

AUTHOR CONTRIBUTIONS

430 GR, FS and PR had the original idea; NP and GR wrote the draft version of the manuscript; EC, SP,
431 CM, EP, MVP, GP, UC, FS contributed to patient identification; NR helped with data collection
432 and management; AP, TP performed the statistical analyses; NP, PR, GR developed the final
433 version of the manuscript, all authors critically revised the final version. GR and NP took
434 responsibility for the submission for publication. No medical writer was involved.

435

436

FUNDING

437 The study was partially supported by a generous donation from QuattroR SGR SpA to the Istituto di
438 Ricerche Farmacologiche Mario Negri IRCCS. The QuattroR SGR SpA did not have any role in
439 study design, in the collection, analysis and interpretation of data, in writing the report, or in the
440 decision to submit the paper for publication.

441

442

ETHICS STATEMENT

443 The COVER 2 study has been approved by the Ethical Committee of Insubria (Varese, Italy; 27
444 July 2021) and registered at the ClinicalTrials.gov (NCT04854824). In COVER 2, participants in
445 the ‘recommended algorithm’ cohort provided written informed consent to their family doctors at
446 enrolment. Subjects in the ‘control’ cohort (from the ORIGIN database) signed a consent form to
447 participate in the ORIGIN study, which also explicitly included consent to use their data for future
448 studies, such as COVER 2.

449

450

451

452

DATA AVAILABILITY STATEMENT

453

454 Sharing individual participant data with third parties was not specifically included in the informed
455 consent form of the study, and unrestricted diffusion of such data may pose a potential threat of
456 revealing participants' identities, as permanent data anonymization was not carried out (patient
457 records were instead de-identified per protocol during the data retention process). To minimize this
458 risk, individual participant data that underlie the results reported in this article will be available after
459 three months and for up to five years following article publication. The researchers shall submit a
460 methodologically sound proposal to Dr. Annalisa Perna (annalisa.perna@marionegri.it), Head of
461 the Laboratory of Biostatistics of the Department of Renal Medicine of the Istituto di Ricerche
462 Farmacologiche Mario Negri IRCCS. To gain access, data requestors will need to sign a data access
463 agreement and obtain the approval of the local ethics committee.

464

465

466

467

REFERENCES

- 468 1. Johns Hopkins CSSE. COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
469 Accessed September 1, 2021. Available at: <https://www.coronavirus.jhu.edu>.
- 470 2. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global
471 Vaccination Programs against SARS-CoV-2/COVID-19. *Vaccines (Basel)* (2021) 9:243.
472 doi:10.3390/vaccines9030243
- 473 3. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia
474 N, Ausiello JC, Wan EY, et al. Extrapulmonary manifestations of COVID-19. *Nat Med* (2020)
475 26:1017–1032. doi:10.1038/s41591-020-0968-3
- 476 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical
477 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
478 retrospective cohort study. *Lancet* (2020) 395:1054–1062. doi:10.1016/S0140-6736(20)30566-
479 3
- 480 5. Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group.
481 Persistent Symptoms in Patients After Acute COVID-19. *JAMA* (2020) 324:603–605.
482 doi:10.1001/jama.2020.12603
- 483 6. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the
484 Pandemic. *JAMA* (2020) 324:1292–1295. doi:10.1001/jama.2020.16747
- 485 7. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
486 Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* (2020) 323:1824–1836.
487 doi:10.1001/jama.2020.6019
- 488 8. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne
489 JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP,
490 Berwanger O, et al. Association Between Administration of Systemic Corticosteroids and
491 Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* (2020)
492 324:1330–1341. doi:10.1001/jama.2020.17023
- 493 9. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. *Science* (2020)
494 367:1412–1413. doi:10.1126/science.367.6485.1412
- 495 10. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL,
496 Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in Hospitalized
497 Patients with Covid-19. *N Engl J Med* (2021) 384:693–704. doi:10.1056/NEJMoa2021436
- 498 11. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Updated 15
499 October 2020. Accessed 17 March 2021. [https://www.who.int/emergencies/diseases/novel-
500 coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-
501 for-covid-19-treatments](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments).
- 502 12. Kim PS, Read SW, Fauci AS. Therapy for Early COVID-19: A Critical Need. *JAMA* (2020)
503 324:2149–2150. doi:10.1001/jama.2020.22813
- 504 13. Available at: <https://www.nice.org.uk/guidance/ng165>, April 3 2020.

- 505 14. Ministero della Salute. Gestione domiciliare dei pazienti con infezione da SARS-CoV-2,
506 aggiornata al 26 aprile 2021. Available at:
507 https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=nu
508 [ll&id=5449](https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=nu). Accessed on 1 September 2021.
- 509 15. Oberfeld B, Achanta A, Carpenter K, Chen P, Gilette NM, Langat P, Said JT, Schiff AE, Zhou
510 AS, Barczak AK, et al. SnapShot: COVID-19. *Cell* (2020) 181:954-954.e1.
511 doi:10.1016/j.cell.2020.04.013
- 512 16. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury
513 and complement-induced coagulopathy in COVID-19. *Nat Rev Nephrol* (2021) 17:46–64.
514 doi:10.1038/s41581-020-00357-4
- 515 17. Suter F, Perico N, Cortinovis M, Remuzzi G. A recurrent question from a primary care
516 physician: How should I treat my COVID-19 patients at home? An update *Clin Med Invest*
517 (2020) 5: 1-9. doi: 10.15761/CMI.1000218.
- 518 18. Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the
519 treatment of COVID-19: Review of literature to propose repositioning of celecoxib for
520 randomized controlled studies. *Int J Infect Dis* (2020) 101:29–32.
521 doi:10.1016/j.ijid.2020.09.1466
- 522 19. Prasher P, Sharma M, Gunupuru R. Targeting cyclooxygenase enzyme for the adjuvant
523 COVID-19 therapy. *Drug Dev Res* (2021) 82:469–473. doi:10.1002/ddr.21794
- 524 20. Suter F, Consolaro E, Pedroni S, Moroni C, Pastò E, Paganini MV, Pravettoni G, Cantarelli U,
525 Rubis N, Perico N, et al. A simple, home-therapy algorithm to prevent hospitalisation for
526 COVID-19 patients: A retrospective observational matched-cohort study. *EClinicalMedicine*
527 (2021) 37:100941. doi:10.1016/j.eclinm.2021.100941
- 528 21. ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor
529 for severe COVID-19: a call to action by the ERA-EDTA. *Nephrol Dial Transplant* (2021)
530 36:87–94. doi:10.1093/ndt/gfaa314
- 531 22. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L,
532 Carlesso E, Castelli G, et al. Risk Factors Associated With Mortality Among Patients With
533 COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med* (2020) 180:1345–
534 1355. doi:10.1001/jamainternmed.2020.3539
- 535 23. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. *Nat Rev*
536 *Nephrol* (2020) 16:705–706. doi:10.1038/s41581-020-00349-4
- 537 24. Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. *SAS SUGI 29 2004*:
538 165-29.
- 539 25. Pocock SJ. *Clinical Trials: A Practical Approach*. Chichester: Wiley; 1983. Chapter 14.
- 540 26. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. *Med*
541 *Mal Infect* (2020) 50:382–383. doi:10.1016/j.medmal.2020.04.002
- 542 27. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J*
543 *Med* (2001) 345:433–442. doi:10.1056/NEJM200108093450607

- 544 28. Carey MA, Bradbury JA, Reboloso YD, Graves JP, Zeldin DC, Germolec DR. Pharmacologic
545 inhibition of COX-1 and COX-2 in influenza A viral infection in mice. *PLoS One* (2010)
546 5:e11610. doi:10.1371/journal.pone.0011610
- 547 29. Ong SWX, Tan WYT, Chan Y-H, Fong S-W, Renia L, Ng LF, Leo Y-S, Lye DC, Young BE.
548 Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. *Clin*
549 *Transl Immunology* (2020) 9:e1159. doi:10.1002/cti2.1159
- 550 30. Ghanem CI, Pérez MJ, Manautou JE, Mottino AD. Acetaminophen from liver to brain: New
551 insights into drug pharmacological action and toxicity. *Pharmacol Res* (2016) 109:119–131.
552 doi:10.1016/j.phrs.2016.02.020
- 553 31. Pandolfi S, Simonetti V, Ricevuti G, Chirumbolo S. Paracetamol in the home treatment of
554 early COVID-19 symptoms: A possible foe rather than a friend for elderly patients? *J Med*
555 *Virol* (2021) 93:5704–5706. doi:10.1002/jmv.27158
- 556 32. Sestili P, Fimognari C. Paracetamol-Induced Glutathione Consumption: Is There a Link With
557 Severe COVID-19 Illness? *Front Pharmacol* (2020) 11:579944.
558 doi:10.3389/fphar.2020.579944
- 559 33. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A,
560 Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, et al. Vascular and
561 upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of
562 individual participant data from randomised trials. *Lancet* (2013) 382:769–779.
563 doi:10.1016/S0140-6736(13)60900-9
- 564 34. Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O, Motola D, Moretti U, Vannacci A,
565 Rafaniello C, Vaccheri A, et al. Risk of acute and serious liver injury associated to nimesulide
566 and other NSAIDs: data from drug-induced liver injury case-control study in Italy. *Br J Clin*
567 *Pharmacol* (2016) 82:238–248. doi:10.1111/bcp.12938
- 568 35. Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, Hardwick HE, Docherty
569 AB, Thwaites RS, Openshaw PJM, et al. Non-steroidal anti-inflammatory drug use and
570 outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a
571 matched, prospective cohort study. *Lancet Rheumatol* (2021) 3:e498–e506.
572 doi:10.1016/S2665-9913(21)00104-1
- 573 36. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes
574 in COVID-19 patients. *Clin Microbiol Infect* (2020) 26:1259.e5-1259.e7.
575 doi:10.1016/j.cmi.2020.06.003
- 576 37. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P.
577 Increased proinflammatory cytokines in patients with chronic stable angina and their reduction
578 by aspirin. *Circulation* (1999) 100:793–798. doi:10.1161/01.cir.100.8.793
- 579 38. Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, McCurdy MT,
580 Tabatabai A, Kumar G, Park P, et al. Aspirin Use Is Associated With Decreased Mechanical
581 Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients
582 With Coronavirus Disease 2019. *Anesth Analg* (2021) 132:930–941.
583 doi:10.1213/ANE.0000000000005292

- 584 39. Bour AM, Westendorp RG, Laterveer JC, Bollen EL, Remarque EJ. Interaction of
585 indomethacin with cytokine production in whole blood. Potential mechanism for a brain-
586 protective effect. *Exp Gerontol* (2000) 35:1017–1024. doi:10.1016/s0531-5565(00)00128-5
- 587 40. Ravichandran R, Purna P, Vijayaragavan S, Kalavakollu RT, Gaidhane S, Kumar RK.
588 Efficacy and Safety of Indomethacin in Covid-19 patients. MedRxiv 2021. doi:
589 10.1101/2020.12.14.20245266.
- 590 41. Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects
591 of glucocorticoids. *Neuroimmunomodulation* (2015) 22:20–32. doi:10.1159/000362724
- 592 42. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med*
593 (2006) 3:e343. doi:10.1371/journal.pmed.0030343
- 594 43. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J,
595 Pinto R, Al-Omari A, Kharaba A, et al. Corticosteroid Therapy for Critically Ill Patients with
596 Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* (2018) 197:757–767.
597 doi:10.1164/rccm.201706-1172OC
- 598 44. Lamontagne F, Agoritsas T, Siemieniuk R, Rochweg B, Bartoszko J, Askie L, Macdonald H,
599 Amin W, Bausch FJ, Burhan E, et al. A living WHO guideline on drugs to prevent covid-19.
600 *BMJ* (2021) 372:n526. doi:10.1136/bmj.n526
- 601 45. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and
602 corticosteroids: should we be limiting their use in the clinical setting? *Ecancermedicalscience*
603 (2020) 14:1023. doi:10.3332/ecancer.2020.1023
- 604 46. Lee K-Y. Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator
605 Therapy. *Int J Mol Sci* (2017) 18: doi:10.3390/ijms18020388
- 606 47. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K,
607 Fox R, Binnian I, Glover V, et al. Inhaled budesonide in the treatment of early COVID-19
608 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med* (2021)
609 doi:10.1016/S2213-2600(21)00160-0
- 610 48. Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, Van Hecke O, Ogburn
611 E, Evans PH, Thomas NPB, et al. Inhaled budesonide for COVID-19 in people at high risk of
612 complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-
613 label, adaptive platform trial. *Lancet* (2021) 398:843–855. doi:10.1016/S0140-6736(21)01744-
614 X
- 615 49. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? *Am*
616 *J Physiol Renal Physiol* (2020) 318:F1454–F1462. doi:10.1152/ajprenal.00160.2020
- 617 50. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients:
618 COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *J Clin Virol* (2020)
619 127:104362. doi:10.1016/j.jcv.2020.104362
- 620 51. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR,
621 Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, et al. Therapeutic
622 Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med* (2021)
623 385:790–802. doi:10.1056/NEJMoa2105911

- 624 52. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G,
625 Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A
626 Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis* (2020)
627 71:2459–2468. doi:10.1093/cid/ciaa530
- 628 53. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J*
629 *Epidemiol* (2003) 158:915–920. doi:10.1093/aje/kwg231
- 630 54. Vandembroucke JP. Observational research, randomised trials, and two views of medical
631 science. *PLoS Med* (2008) 5:e67. doi:10.1371/journal.pmed.0050067
- 632 55. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I, CoviCare Study Team.
633 Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-
634 19 in an Outpatient Setting. *Ann Intern Med* (2021) 174:1252–1260. doi:10.7326/M21-0878
- 635
- 636

637

FIGURE CAPTION

638

639 **Figure 1. Kaplan-Meier curves for the primary endpoint of hospital admission.**

640 Kaplan-Meier curves show the proportion of patients who required hospitalization in the two
641 treatment cohorts. Grey line, ‘recommended algorithm’ treatment cohort; black line, ‘control’
642 cohort. P-value for treatment comparison was assessed by survival analysis for clustered data.

643

644 **Figure 2. Cumulative length of hospital stay and related costs in the two study cohorts.**

645 Cumulative days of hospitalization (**A**) and cumulative costs for hospital stay (**B**) in the
646 ‘recommended’ treatment cohort and in the ‘control’ cohort. Grey columns, ‘recommended’
647 treatment cohort; white columns, ‘control cohort’.

648

649

650

651 **Table 1.** Demographic and early symptoms associated with COVID-19 illness in the two treatment
652 cohorts.

	Overall (n=216)	Recommended treatment cohort (n=108)	Control cohort (n=108)	P value
Demographic characteristics				
<i>Age, years</i>				
18-40	43 (19.90)	23 (21.30)	20 (18.52)	0.968
41-65	127 (58.80)	63 (58.34)	64 (59.26)	
66-75	23 (10.65)	11 (10.18)	12 (11.11)	
>75	23 (10.65)	11 (10.18)	12 (11.11)	
Mean age ± SD	53.3±15.4	53.1±15.8	53.5±15.1	0.847
Males, n (%)	84 (38.89)	46 (42.59)	38 (35.18)	0.329
Comorbidities, n (%)				
Cardiovascular disease	19 (8.80)	8 (7.41)	11 (10.18)	0.652
Hypertension	51 (23.61)	23 (21.30)	28 (25.93)	0.522
Diabetes mellitus	5 (1.85)	1 (0.93)	4 (3.70)	0.369
Overweight/Obesity	33 (15.28)	11 (10.18)	22 (20.37)	0.057
Chronic kidney disease	1 (0.46)	1 (0.93)	0 (0)	1.000
Early symptoms, n (%)				
Fever	154 (71.30)	76 (70.37)	78 (72.22)	0.880
Myalgia	110 (50.92)	52 (48.15)	58 (53.70)	0.496
Arthralgia	37 (17.13)	33 (30.55)	4 (3.70)	0.001
Tiredness/exhaustion	157 (72.68)	74 (68.52)	83 (76.85)	0.222
Dyspnea	62 (28.70)	28 (25.93)	34 (31.48)	0.452
Chest pain	32 (14.81)	14 (12.96)	18 (16.67)	0.566
Headache	87 (40.28)	46 (42.59)	41 (37.96)	0.579
Lack of appetite	64 (29.63)	26 (24.07)	38 (35.18)	0.101
Cough	117 (54.17)	65 (60.18)	52 (48.15)	0.101
Sore throat	57 (26.39)	35 (32.41)	22 (20.37)	0.063
Rhinitis	59 (27.31)	31 (28.70)	28 (25.93)	0.760
Vomiting/nausea	33 (15.28)	13 (12.04)	20 (18.52)	0.256
Diarrhea	38 (17.59)	16 (14.81)	22 (20.37)	0.372
Red eyes	22 (10.18)	7 (6.48)	15 (13.89)	0.114
Vertigo	11 (5.09)	10 (9.26)	1 (0.93)	0.010
Sicca syndrome	1 (0.46)	1 (0.93)	0 (0)	1.000
Anosmia	88 (40.74)	37 (34.26)	51 (47.22)	0.071
Ageusia	102 (47.22)	42 (38.89)	60 (55.55)	0.020

653 Data are numbers (percentages). Between-group differences were assessed by Fisher's exact test.

654 **Table 2.** Clinical course of hospitalized patients in the two cohorts.

Cohort	Reason for hospital admission	Hospitalisation (days)	Oxygen therapy* (yes/no)	CPAP (yes/no)	CPAP (days)	Mechanical ventilation (yes/no)	Mechanical ventilation (days)	ICU admission (yes/no)	ICU admission (days)	Sequelae at discharge (yes/no)
<i>Control</i>										
Control	Dyspnea (interstitial pneumonia)	12	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	26	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	4	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	12	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	4	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	13	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	17	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia) and epigastralgia	6	No	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia)	10	Yes	No	-	No	-	No	-	No
Control	Dyspnea (interstitial pneumonia) and epigastralgia	9	Yes	No	-	No	-	No	-	No

Control	Dyspnea (interstitial pneumonia) and gastrointestinal symptoms	8	Yes	No	-	No	-	No	-	No
Control	Dyspnea (Pulmonary thromboembolism)	20	No	No	-	No	-	No	-	No
<i>'Recommended'</i>										
'Recommended'	Dyspnea (interstitial pneumonia)	19	Yes	Yes	6	No	-	No	-	No

655 *Conventional oxygen therapy (oxygen delivered by nasal tube, nasal cannula, or face mask). ° CPAP, continuous positive airway pressure; ICU, intensive care unit.

656 **Table 3.** Treatment at home in the two study cohorts.


	Recommended treatment cohort (n=108)	Control cohort (n=108)	P value
Relatively selective COX-2 inhibitors	74 (68.52)	4 (3.70)	P<0.001
Nimesulide	36/74 (48.65)	1/4(25.00)	
Morniflumate	0 (0)	2 (50.00)	
Celecoxib	38/74 (51.35)	0/ (0)	
Etoricoxib	0/ (0)	1/ (25.00)	
Other NSAIDs	34 (31.48)	82 (75.93)	P<0.001
Aspirin	15/34 (44.12)	5/82 (6.10)	
Ketoprofen	7/34 (20.59)	4/82 (4.88)	
Ibuprofen	10/34 (29.41)	12/82 (14.63)	
Indomethacin	0/ (0)	0/ (0)	
Paracetamol	9/34 (26.47)	74/82 (90.24)	
Corticosteroids	28 (25.93)	7 (6.48)	P<0.001
Anticoagulants	3 (2.78)	2 (1.85)	P=1.000
Antibiotics	41 (37.96)	26 (24.07)	P=0.039
<i>Azithromycin</i>	20/41 (48.78)	7/26 (26.92)	
<i>Amoxicillin and clavulanic acid</i>	0/41 (0)	3/26 (11.54)	
Need of oxygen*	10 (9.26)	2 (1.85)	P=0.033

657 Data are n/N (percentages). COX-2, cyclooxygenase-2; NSAIDs, nonsteroidal anti-inflammatory
658 drugs. * Need for oxygen therapy at home. Between-group differences were assessed by Fisher's
659 exact test.

Table 4. Major secondary outcomes.

	Recommended treatment cohort (n=108)	Control cohort (n=108)	Nominal P value
Time from symptoms onset and start of anti-inflammatory therapy (days)	1.7 ± 3.3	-	-
Rate of resolution of major symptoms*	105/108 (97.2)	101/108 (93.5)	P=0.332
Rate of persistence of other symptoms [°]	22/108 (20.4)	69/108 (63.9)	P<0.001**
Persistence of other symptoms (days)			
< 30	6/22 (27.3)	13/69 (18.8)	P=0.385
30-60	8/22 (36.4)	6/69 (8.7)	P=0.0043**
>60	8/22 (36.4)	50/69 (72.5)	P=0.0043**

Data are n/N (percentages) or mean ± SD, as appropriate. * defined as complete recovery from major symptoms, i.e., no fever, SpO₂>94% and/or no dyspnea, no cough, no rhinitis, no pain (myalgia, arthralgia, chest pain, headache, sore throat), no vertigo, no nausea, vomiting or diarrhea, no sicca syndrome or red eyes; [°] defined as recovery from major COVID-19 symptoms, but persistence of symptoms such as anosmia, ageusia/dysgeusia, lack of appetite, fatigue. ** Significant after Bonferroni adjustment for multiple tests.



Patients at risk

'Recommended'	108	85	31	9	4	2	2
Control	108	69	41	29	20	17	16

Figure 1




Figure 2